TABLE 4.
Clinical benefit of buprenorphine transdermal system throughout long-term open-label treatment
| Assessment scale | End of double-blinded trial | Last open-label trial visit | P |
|---|---|---|---|
| VAS pain intensity (past week) | 38.5±17.9 | 32.9±28.1 | 0.5431 |
| Ordinal pain intensity (past week) | 1.6±0.6 | 1.6±0.8 | 0.8454 |
| VAS pain intensity (past 24 h) | 39.4±19.1 | 13.2±20.2 | 0.0001 |
| Ordinal pain intensity (past 24 h) | 1.7±0.6 | 1.6±0.9 | 0.5253 |
| Overall Pain and Sleep | 156.0±113.7 | 146.3±116.8 | 0.5647 |
| Overall pain and disability | 26.9±15.2 | 25.6±18.3 | 0.5767 |
| Average Quebec Back Pain Disability Scale | 2.2±0.9 | 2.2±1.1 | 0.9150 |
| SF-36 standard physical component | 28.6±9.3 | 25.3±10.7 | 0.0226 |
| SF-36 standard mental component | 47.6±12.8 | 49.3±17.9 | 0.9734 |
Data presented as mean ± SD. SF-36 Short-Form 36 Health Survey; VAS Visual analogue scale